Clinical Trial Update: IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2) [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 study evaluating IMB-1018972 for improving cardiac energetics in adults with type 2 diabetes and obesity-related…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Cardiomyopathy
• Heart Failure with Preserved Ejection Fraction
• Type 2 Diabetes Mellitus

Drugs mentioned

• IMB-1018972

Snippet

Sponsor: Imbria Pharmaceuticals, Inc. | Conditions: Type 2 Diabetes, Diabetic Cardiomyopathies | Phase 2 | Status: COMPLETED